BEVERLY HILLS, Calif., April 8, 2014 /PRNewswire/ -- Life Stem Genetics, Inc. (LIFS), an emerging company in the advancement of adult stem cell therapies, today announced the appointments of Dr. Roberto Fernandez Vina, Dr. Ranbir Singh Gill, and Dr. Praveen Gill to its Medical Advisory Board.

Dr. Roberto Fernandez Vina

Born and educated in Argentina, Dr. Roberto Fernandez Vina, MD Cardiology, is a pioneer in the development of multiple adult stem cell therapies, protocols, and medical devices. Dr. Vina has performed many diabetes stem cell treatments around the world. In 2003, he organized a ground-breaking trial for the implantation of stem cells into recent heart attack victims receiving bypass operations. In 2005, he became the first doctor to prove in a clinical trial that adult stem cells significantly improved the lives of type-2 diabetes patients. During 2006 to 2007, he pioneered stem cell treatments for emphysema and Chronic Obstructive Pulmonary Disorder (COPD). Dr. Vina is also an Argentine Interventional Cardiologist Professor and serves as Chief of Endovascular Therapeutics Service at the Benetti Foundation, Argentina.

Dr. Ranbir Singh Gill

Dr. Ranbir Singh Gill, MD Internal Medicine, received his medical degree from the prestigious Medical College of Amritsar, India, in 1985 and completed his MD in Internal Medicine in 1992. Specializing in cardiology, he completed a Fellowship in Cardiology from Escorts Heart Institute & Research Centre in New Delhi, India, under the guidance of cardiac surgeon Dr. N. Trehan. In pursuit of his passion, Dr. Gill regularly attends national and international cardiology conferences and has traveled to remote areas of India where he performed echocardiography for the detection and prevalence of heart disease in these less densely populated areas. He has a keen interest in the role genetics play in the prevention of cardiomyopathy. He is married to Dr. Praveen Gill who also serves on Life Stem's Medical Advisory Board.

Dr. Praveen Gill

Dr. Praveen Gill, MD Pediatrics, hails from India and was clinical attache to the Post Graduate Institute and panel member of the Fortis Group of Hospitals, both in India. Dr. Gill served as assistant professor at the SGRD Medical Institute & Research Centre in Amritsar, India, and is a known figure in the field of pediatrics. Specializing in neonatology, she has performed genetic screening and carrier detection and believes that pediatricians and geneticists can work in unison to strengthen the clinical applications of genetics to pediatric endocrinology. Her husband is Dr. Ranbir Singh Gill who also serves on Life Stem's Medical Advisory Board.

About Life Stem Genetics

Life Stem Genetics, symbol: LIFS, is a fully reporting, audited public company. LIFS is a progressive healthcare company focused on Adult Stem Cell ("ASC") healing therapies and stem cell related products. Stem cells have been utilized in the successful treatment of a variety of ailments. Today, advanced ASC therapies are being offered to patients as an efficient and painless alternative treatment for a wide range of ailments including, but not limited to, orthopedic injuries, neurological disorders such as Parkinson's and Alzheimer's, cancer, arthritis, diabetes, cardiology, multiple sclerosis, as well as age management.

Find the full disclosure and disclaimer at the following links:

ABOUT LIFESTEM GENETICS (direct link: http://www.lifestemgenetics.com/aboutus.php)

DISCLAIMER (direct link: http://www.lifestemgenetics.com/disclaimer.php)

CONTACT: Life Stem Genetics, Shareholder Relations, Office +1-310-279-5234, info@LifeStemGenetics.com, http://www.LifeStemGenetics.com

SOURCE Life Stem Genetics

Copyright 2014 PR Newswire

Life Stem Genetics (CE) (USOTC:LIFS)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Life Stem Genetics (CE) Charts.
Life Stem Genetics (CE) (USOTC:LIFS)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Life Stem Genetics (CE) Charts.